Search Results
636 results
Your search is now limited to «Diabetes Treatments» expert search.
American Diabetes Journals 03/20/2019 15:00
OBJECTIVE. To evaluate the safety and efficacy of IONIS-GCGR Rx , a 2'- O -methoxyethyl antisense oligonucleotide targeting the glucagon receptor (GCGR), and the underlying mechanism of liver transaminase increases in patients with type 2 diabetes on stable metformin therapy. RESEARCH DESIGN AND METHODS. In three phase 2, randomized, double-blind studies, patients with type 2 diabetes on metformin received weekly subcutaneous injections of IONIS-GCGR Rx (50–200 mg) or placebo for 13 or 26 weeks. RESULTS. Significant reductions in HbA 1c were observed after IONIS-GCGR Rx treatment versus placebo at week 14 (–2.0% 200 mg, –1.4% 100 mg, –0.3% placebo; P < 0.001) or week 27 (–1.6% 75 mg, –0.9% 50 mg, –0.2% placebo; P < 0.001).
More from American Diabetes Journals:
FeedNavigator 03/20/2019 12:47
Chronic disease management platform Hello Heart will now integrate with LifeScan OneTouch meters as part of its program for diabetes management.
More from FeedNavigator:
Healio News 03/20/2019 11:30
Potential diabetic retinopathy treatment fails to meet phase 2b study endpoint.
More from Healio News:
Medindia.com 03/20/2019 08:24
Another study on diabetic rats revealed that drinking amla juice may help treat certain health problems widespread in people with type 1 diabetes mellitus.
More from Medindia.com:
Invokana is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of diabetes ...
More from Global Banking & Finance Review:
WN.com 03/20/2019 01:53
Artificial intelligence in healthcare uses an algorithms and software to approximate human cognition in analysis of complex medical data.
More from WN.com:
Becker's Hospital Review 03/19/2019 17:06
One Drop, a digital health company focused on diabetes care management, will offer its diabetes therapy services as part of Amazon's at-home medical devices brand Choice.
More from Becker's Hospital Review:
ClinicalTrials.gov 03/19/2019 10:26
Conditions : Diabetic Foot; Diabetic Foot Ulcer; Ulcer Foot Interventions : Other: Human Autologous Homologous Skin Construct; Other: Additional Outer Dressing Applicaiton; Other: Offloading; Other: Fibracol Wound Dressing Sponsors : Professional Education and Research Institute; Polarity TE Recruiting.
More from ClinicalTrials.gov:
Top Class Actions 03/19/2019 07:00
Because these diabetes drugs work through kidney stimulation, a patient taking one of these drugs may feel the urge to urinate more frequently.
More from Top Class Actions:
Business Wire 03/18/2019 09:00
Likewise, Juan Carlos’ addition to the team provides guidance and experience to advance the company’s clinical pipeline as we develop novel, disease-modifying therapies for metabolic diseases, including type 2 diabetes and NAFLD/NASH.
More from Business Wire:
ENDPOINTS 03/18/2019 08:46
Roughly two years after raising $40 million in a private placement, Aerpio Pharmaceuticals’ lead experimental eye drug has hit a roadblock after failing a mid-stage study in patients with non-proliferative diabetic retinopathy (NPDR) — the earliest stage of diabetic eye disease, which occurs when high blood sugar levels cause damage to blood vessels in the retina ...
More from ENDPOINTS:
Lifeboat News: The Blog 03/16/2019 06:22
It is often not the lack of a cure, but the lack of will. Many great strides have been made with diabetes, when people stopped trying to develop medicines, and instead focused on how to enable the body to produce insulin. Restoration of insulin independence and normoglycemia has been the overarching goal in diabetes research […]
More from Lifeboat News: The Blog:
Diabetes In Control News 03/15/2019 20:09
Conclusions from an analysis assessing over 20,000 people with diabetes in the REACH (Reduction of Atherothrombosis for Continued Health) registry showed a 31% decrease in heart failure mortality rate in patients who were treated with metformin in comparison with those patients who were not on metformin ...
More from Diabetes In Control News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications